Seminars in Thrombosis and Hemostasis
Extended Anticoagulation Therapy with Rivaroxaban for Cancer-Associated Low-Risk Pulmonary Embolism According to Status of Concomitant Deep Vein Thrombosis: Insights from the ONCO PE Randomized Trial
Abstract The ONCO PE trial showed that 18-month rivaroxaban was superior to 6-month rivaroxaban for preventing recurrent venous thromboembolism (VTE) in patients with cancer-associated low-risk pulmonary embolism (PE). However, the influence of concomitant deep vein thrombosis (DVT) on this benefit was unclear. The current post-hoc subgroup analysis of the ONCO PE trial categorized patients into DVT subgroup (N = 104) and no DVT subgroup (N = 74) based on the presence or absence of a concomitant DVT at PE diagnosis …